Pulmonary tuberculosis (TB) is an endemic infectious disease in Taiwan. A retrospective study was conducted to define clinical manifestations and outcomes of patients with pulmonary TB among hematopoietic stem cell transplantation (HSCT) recipients. We identified eight out of 350 HSCT recipients as having pulmonary TB over a 6-year period. The relative risk of having pulmonary TB after HSCT was 13.1-fold higher than in the general population. There was a trend toward increased risk of having pulmonary TB in allogeneic HSCT as compared to autologous HSCT (4.8 ± 1.8% vs 0, P = 0.067). All the eight patients with pulmonary TB received allogeneic HSCT and most (seven of eight patients) developed the infection during treatment for GVHD. Computed tomography of the chest was normal in one patient, with the rest showing either interstitial (two patients) or alveolar infiltrates (five patients) at the onset of pulmonary TB. The four fatal cases had an obviously shorter duration between HSCT and onset of infection. Our data suggest that pulmonary TB in HSCT recipients is not uncommon in this endemic area. Therefore, an effective strategy of prophylactic treatment for candidates and recipients of allogeneic HSCT, who may have latent pulmonary TB infection, must be developed. Bone Marrow Transplantation (2001) 27, 1293-1297. Keywords: pulmonary tuberculosis; graft-versus-host disease; hematopoietic stem cell transplantation; prophylactic anti-tuberculous treatment Hematopoietic stem cell transplantation (HSCT) recipients are prone to acquire several kinds of opportunistic infections during the early stages of engraftment post-BMT and while receiving immunosuppressive therapy for GVHD.
Hematopoietic stem cell transplantation (HSCT) recipients are prone to acquire several kinds of opportunistic infections during the early stages of engraftment post-BMT and while receiving immunosuppressive therapy for GVHD. 1, 2 The incidence, clinical characteristics, and management of opportunistic infections caused by bacterial, fungal and viral agents have been well known for decades. However, few publications have described the incidence and outcome of tuberculosis (TB) in HSCT recipients. 1, [3] [4] [5] [6] [7] [8] [9] [10] Pulmonary TB in Taiwan is common: 30 cases/10 5 inhabitants/year for age Ͻ50 years and 221 cases/10 5 inhabitants/year for age у50 years, respectively. 11 In 1998, the prevalence of TB in the adult (age у20 years) general population was 0.65%. 11 In HSCT recipients, the disease may pose an even greater problem, since the impaired cellular immunity renders these patients susceptible to infection, as is the case in those with autoimmune disorders or compromised immunity. For example, in HIV-infected patients, the incidence of pulmonary TB is 17.3%, making it the second most common infection after Pneumocystis carinii pneumonia. 11, 12 In this report, a retrospective study was conducted to define the characteristics and incidence of pulmonary TB in HSCT recipients during a 6-year period in a tertiary referral hospital. Demographic data, risk factors, clinical presentations and outcomes are described. Chest radiographs and computed tomography (CT) of patients with pulmonary TB were reviewed.
Patients and methods

Patients
Three hundred and fifty patients who underwent HSCT between March 1994 and March 2000 at the National Taiwan University Hospital, a tertiary referral central in Northern Taiwan, were enrolled in this retrospective study. There were 255 allogeneic HSCT and 95 autologous HSCT. The mean age at transplantation was 24.9 ± 14.7 years. The mean follow-up period was 25 ± 22 months. The sources of stem cells in allogeneic HSCT were bone marrow in 206 patients and G-CSF-mobilized PBSC in 49 patients. Preconditioning regimens included high-dose cytarabine, high-dose cyclophosphamide, and other regimens with or without total body irradiation. Pre-HSCT evaluation of the respiratory system included chest radiograph, high-resolution CT (HRCT) and pulmonary function tests within 1 month prior to transplantation. Sputum smears and cultures for acid-fast bacilli were not included routinely. GVHD prophylaxis consisted of standard cyclosporin and shortcourse methotrexate. Patients who developed GVHD received methylprednisolone and cyclosporin (CsA) for the acute form and prednisolone and CsA for the chronic form.
The diagnosis of active pulmonary TB required: (1) Medical records of patients who fulfilled the definitions of active pulmonary TB were reviewed. Demographic data, underlying diseases, duration between HSCT and diagnosis of pulmonary TB, patterns of chest radiographs at diagnosis of infection, diagnostic methods, treatments prescribed, and outcomes were recorded. Serial chest radiographs and CTs between pre-HSCT evaluation and post-HSCT follow-up were reviewed to define the development of pulmonary TB in time sequence.
Statistical analysis
Data were analyzed using the Statistical Package for Social Science software version 9.0 (SPSS, Chicago, IL, USA). The individual survival times of the 350 HSCT recipients were obtained from our BMT data bank. The cumulative probability of having pulmonary TB was processed by the Kaplan-Meier method. A log-rank test was used to compare the differences between subgroups of HSCT recipients. Differences were considered significant at a P value of less than 0.05.
Relative risk estimates were determined for incidence of TB between HSCT recipients and the general population with the method of standardized morbidity ratio (SMR). 13 Reference data of the general population were obtained from the annual survey of TB in Taiwan. 11 We can estimate the expected incidence of TB in our patients according to the data from the general population. Because our patients were enrolled over a 6-year period, the observed TB incidence in our patients each year was compared with the expected TB incidence of the corresponding year and the overall relative risk during 6-year period was analyzed by the method of SMR.
Results
Demographic data and cumulative incidence of pulmonary TB in HSCT
We identified eight (2.3%) HSCT recipients out of 350 who fulfilled the diagnosis of active pulmonary TB between March 1994 and March 2000. Demographic data are summarized in Table 1 . Median age was 42 years old (range 11-50). Six patients received TBI during preconditioning. All eight patients experienced GVHD and all except one (patient No. 1) had pulmonary TB during treatment for GVHD. Patients with acute GVHD received methylprednisolone pulse therapy for 3 days plus CsA and those with chronic GVHD received prednisolone and CsA; the dose was adjusted according to the clinical conditions after treatment.
The estimated probabilities of having TB between allogeneic and autologous HSCT are 4.8 ± 1.8% vs 0%, respectively, and there is a trend of increased risk of having TB in allogeneic HSCT with a P value of 0.067. There is a 6.7 ± 3.7% probability of having infection for allogeneic PBSCT and 4.3 Ϯ 2.1% probability for allogeneic BMT and the difference between the two groups is statistically insignificant with a P value of 0.26 ( Figure 1 ). The SMR in HSCT was 13.1 (95% CI, 6.6-26.2) as compared to the general population; that is, the relative risk of having pulmonary TB after HSCT was 13.1 times greater than in the general population.
Clinical presentations and diagnostic procedures
All the eight patients had received BCG vaccination according to the national vaccination protocol, and no patient had undergone anti-TB treatment prior to transplant. One patient (patient No. 2) had a family member who had acquired pulmonary TB pre-HSCT. As the PPD skin test was not routinely performed before transplantation, no data could be obtained except from one patient (patient No. 3). The patient was a pediatric allogeneic BMT recipient. The initial chest radiograph disclosed diffuse interstitial pulmonary infiltrates, which progressed into acute respiratory distress syndrome (ARDS) with a fatal outcome.
14 The child had received Bacille Calmette-Guérin (BCG) vaccination and the result of his purified protein derivative (PPD) tuberculin test was negative at his last admission. The fifth patient experienced an episode of febrile neutropenia with pneumonia during consolidation chemotherapy and sputum cultures obtained during this period yielded M. tuberculosis, which had been reported 1 month after BMT. Three patients had extrapulmonary involvement including the liver (patient No. 2), bone marrow (patient No. 6), and neck lymph nodes and blood (patient No. 8).
On reviewing the pre-HSCT chest radiographs and CT scans, two patients (patients Nos 4 and 6) had old TB fibrotic lesions. The chest radiographic patterns of pulmonary TB at the onset of infection were mainly alveolar processes involving either lobar or multiple segments without preferential distribution in the upper lobe in five patients, interstitial pneumonitis with diffuse linear density and ground glass attenuation on chest CT in two patients (patients Nos 3 and 8) (Figure 2 ) and normal in one patient (patient No. 5).
The median time interval between performance of HSCT and diagnosis of pulmonary TB was 3.8 months (range 1-33.5). Patients who had the diagnosis established by sputum cultures (patient Nos 1, 5, 6 and 7) had a median delay of 25 days (range 20-40) in anti-TB treatment due to the slow growth of M. tuberculosis in culture media. The median The sputum cultures done half a month pre-HSCT grew M. tuberculosis 1 month after HSCT. b Patient has been noted to have pulmonary TB for 5 months and still under anti-TB treatment. MDS = myelodysplastic syndrome; RAEB = refractory anemia with excess blasts; RAEB-T = RAEB in transformation; APL = acute promyelocytic leukemia; NHL = non-Hodgkin's lymphoma; allo-BMT = allogeneic BMT; PBSCT = PBSC transplantation; NA = not accessible; S/C = sputum culture; AFB = smear for acid-fast bacilli; LN = lymph nodes; Int = interstitial pattern; ARDS = acute respiratory distress syndrome; HERZ denotes anti-TB drugs including isoniazid (H), ethambutol (E), rifampicin (R), pyrazinamide (Z); OS denotes antibiotics of ofloxacin and streptomycin; CAE denotes antibiotics of ciprofloxacin, amikacin, ethambutol; GF = graft failure; R = leukemia relapse. Isolates of M. tuberculosis recovered by diagnostic methods were all sensitive to isoniazid, ethambutol, rifampicin, and streptomycin.
Courses of treatment and outcomes
Six patients received first-line anti-TB treatment, of whom three patients (patient Nos 1, 2 and 4) experienced resolution of infection with treatment lasting between 9 and 12
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Discussion
In this study, we recognize that it is not uncommon to find patients undergoing allogeneic HSCT who have pulmonary TB and that a delay in diagnosis of pulmonary TB in these patients in an endemic area could have a pivotal impact on their outcomes. According to several series reported, the frequency of M. tuberculosis infections in HSCT recipients has varied from less than 0.1 to 5.5% (Table 2 ). In our study, we identified eight (2.29%) HSCT recipients out of 350 as having active pulmonary TB and estimated the risk of cumulative incidence of having pulmonary TB after HSCT to be 13.1-fold greater than in the general population in Taiwan. We also found a trend of increased probability of infection in allogeneic HSCT as compared to autologous BMT recipients. However, this finding was not statistically significant, which may be attributed to the short duration of follow-up and the small number of cases. The incidence of TB infection in HSCT may still be underestimated due to the nonspecific clinical presentation, time-consuming ineffective diagnostic methods and overwhelming clinical course of GVHD masking the picture of TB infection.
The cellular immunity of HSCT recipients is extremely disrupted after preconditioning with high-dose chemotherapy and total body irradiation. Immune reconstitution improves steadily after engraftment and is complete by 1 to 2 years post BMT. If GVHD develops, cellular immunity is impaired due to dysregulation and abnormal clonal expansion of T cells; the patient's condition will further deteriorate with immunosuppressive therapy. 15, 16 Opportunistic infections including bacterial, viral, and fungal pathogens can occur at this time. 1, 2 In an area where tuberculosis is endemic, the general population is exposed to the tubercle bacillus for its whole life. However, initial host response can effectively eradicate the bacillus. Bacilli may become dormant without causing clinical disease, such that this is regarded as latent infection manifesting only by a positive tuberculin skin test. 17 For allogeneic HSCT recipients acquiring GVHD, the dysregulation of immune T cells would render these patients immunologically unable to defend themselves against M. tuberculosis. 8 As noted in our study, the majority of patients had pulmonary TB during the active stage of GVHD. The cause of infection in our patients may be attributed to reactivation of latent TB infection in two patients due to pre-HSCT old pulmonary TB lesions. Whether the TB was due to primary infection or reactivation post transplant was undetermined in the other six cases on account of the limited clinical information reviewed retrospectively. Although PBSCT is now widely use for its benefits of rapid hematologic recovery after intensive chemotherapy, the potentially increased risk of GVHD after allogeneic PBSCT should raise more concerns in an area where TB is endemic. 18 The clinical presentations of pulmonary TB in HSCT recipients were nonspecific. 8, 9 In contrast to the recently reported case series in Spain, 10 the onset of infection in our patients was mainly (five out of eight patients) in the first 6 months post HSCT and the devastating clinical courses of the patients who died did not suggest pulmonary TB as being instrumental in their deterioration. Reasons for the early onset of infection may imply a higher incidence of latent TB and a higher probability of exposure in our patients than the general population. Due to the slow growth of tubercle bacilli in culture media, anti-TB treatment was usually delayed until results of the isolates were confirmed. Our pediatric patient had a primary infection with M. tuberculosis. His history of BCG vaccination and the result of the PPD tuberculin test with such defective cellular immunity were useless in the early detection of infection. Since clinical pictures and conventional laboratory studies were not reliable in establishing a diagnosis of pulmonary TB in immunosuppressed hosts, we suggest that newly developed molecular techniques, such as PCR, should be included routinely to improve diagnostic sensitivity and efficacy.
According to clinical and radiographic presentations, reactivation of latent TB infections is likely in most of our patients. It raises the issue of prophylactic treatment for remote TB infection in recipients of HSCT. In a recent study in Hong Kong anti-TB therapy was administered to HSCT recipients with a positive outcome. 8 However, we have to weigh the benefits of propylactic treatment against the problems associated with side-effects from anti-TB drugs. The new recommendations from the American Thoracic Society suggest treating high-risk persons who have a positive tuberculin test. 19 In Taiwan where BCG has been used for mass-vaccination, the use of the PPD tuberculin test to determine the presence of latent TB infections is greatly reduced. The value of the PPD tuberculin test is also unclear in patients with hematologic malignancies receiving immunosuppressive therapy. Detection of active TB infection in the general population and in immunocompromised hosts depends mainly on clinical suspicion and laboratory examination. Of more concern is the impact of a higher incidence of TB infection in HSCT recipients and the difficulties in preventing spread to health care workers. We suggest that, in endemic areas, recipients of allogeneic HSCT are regarded as high-risk persons and should receive prophylactic anti-TB treatment when the following conditions prevail: (1) Old pulmonary TB lesion present regardless of prior anti-TB treatment. (2) Positive PPD test results (diameter of induration greater than 10 mm) pre-HSCT and/or (3) presence of GVHD.
In summary, we identified a much higher risk of pulmonary TB in HSCT recipients as compared to that in the general population of Taiwan. Earlier onset of infection was also associated with a poorer prognosis. According to this retrospective study, pulmonary TB should be considered as a significant opportunistic infection post HSCT in an endemic area. However, timely diagnosis may be difficult due to the nonspecific presentations of the disease. Therefore, a strict standardized diagnostic and monitoring strategy should be developed for the management of pulmonary TB in HSCT recipients. A consensus for prophylactic treatment of latent pulmonary TB infection in candidates for and recipients of HSCT should be set up as soon as possible to improve patient outcomes.
